Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $142.72. Shares of BNTX stock opened at $123.77 on Monday. BioNTech SE has ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $142.72. BNTX has been the subject of several recent research reports.

Health and pharmaceutical stocks — including Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX ... what lies ahead for the stock. The average of price targets set by Wall Street ...

If an investor was to purchase shares of BNTX stock at the current price level of $114.21/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

BioNTech SE Sponsored ADR (BNTX) closed the last trading session at $112.76, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...